leflunomide has been researched along with Vasculitis in 14 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a leg ulcer in a rheumatoid arthritis (RA) patient under treatment with leflunomide, discuss the influence of the drug on the aetiopathogenesis of the ulcer and describe its successful treatment." | 7.73 | Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. ( Dissemond, J; Goos, M; Knab, J, 2005) |
| "Vasculitis as a complication of leflunomide therapy in the treatment of rheumatoid arthritis has been reported." | 7.72 | Vasculitis associated with the use of leflunomide. ( Gan, BS; Harth, M; Lazarescu, A; Macdonald, J; Zhong, T, 2004) |
| "Cases of toxic neuropathy have been observed during treatment of rheumatoid arthritis with leflunomide." | 3.74 | Peripheral neuropathy associated with leflunomide: is there a risk patient profile? ( Bentaberry, F; Dehais, J; Dumoulin, C; Haramburu, F; Martin, K; Miremont-Salamé, G; Schaeverbeke, T, 2007) |
| "We report the case of a leg ulcer in a rheumatoid arthritis (RA) patient under treatment with leflunomide, discuss the influence of the drug on the aetiopathogenesis of the ulcer and describe its successful treatment." | 3.73 | Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. ( Dissemond, J; Goos, M; Knab, J, 2005) |
| "Vasculitis as a complication of leflunomide therapy in the treatment of rheumatoid arthritis has been reported." | 3.72 | Vasculitis associated with the use of leflunomide. ( Gan, BS; Harth, M; Lazarescu, A; Macdonald, J; Zhong, T, 2004) |
| "This small vessel vasculitis is characterised by palpable purpura, abdominal pain, arthritis or arthralgia and kidney involvement." | 3.01 | Interventions for preventing and treating kidney disease in IgA vasculitis. ( Craig, JC; Hahn, D; Hodson, EM, 2023) |
| "The perforating dermatoses are a group of disorders characterized by transepidermal elimination of a material from the upper dermis." | 2.58 | Perforating disorder secondary to leflunomide and review of the literature of medications associated with perforating disorder. ( Keeley, JM; Pavlidakey, P; Sami, N, 2018) |
| "Vasculitis is a complex area for the evaluation of newer therapies due to the heterogeneity between and within syndromes with multisystem manifestations." | 2.45 | Newer therapies for vasculitis. ( Hiemstra, TF; Jayne, D, 2009) |
| "New prospects for the treatment of vasculitis include novel immunosuppressive agents (e." | 2.41 | Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. ( Kallenberg, CG; Stegeman, CA; Tervaert, JW, 2001) |
| " Pulse cyclophosphamide has been shown to be as effective as the standard therapy in necrotizing vasculitides; however, an alarmingly high rate of infections was observed in this study in both arms possibly related to the high dosage of GCs." | 2.40 | New concepts in treatment protocols for severe systemic vasculitis. ( Gross, WL, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Hahn, D | 1 |
| Hodson, EM | 1 |
| Craig, JC | 1 |
| Keeley, JM | 1 |
| Pavlidakey, P | 1 |
| Sami, N | 1 |
| Hiemstra, TF | 1 |
| Jayne, D | 2 |
| Pettersson, T | 1 |
| Karjalainen, A | 1 |
| Cunnane, G | 1 |
| Warnock, M | 1 |
| Fye, KH | 1 |
| Daikh, DI | 1 |
| Chan, AT | 1 |
| Bradlow, A | 1 |
| McNally, J | 1 |
| Bruyn, GA | 1 |
| Macdonald, J | 1 |
| Zhong, T | 1 |
| Lazarescu, A | 1 |
| Gan, BS | 1 |
| Harth, M | 1 |
| Knab, J | 1 |
| Goos, M | 1 |
| Dissemond, J | 1 |
| de Groot, K | 1 |
| Martin, K | 1 |
| Bentaberry, F | 1 |
| Dumoulin, C | 1 |
| Miremont-Salamé, G | 1 |
| Haramburu, F | 1 |
| Dehais, J | 1 |
| Schaeverbeke, T | 1 |
| van Woerkom, JM | 1 |
| Kruize, AA | 1 |
| Geenen, R | 1 |
| van Roon, EN | 1 |
| Goldschmeding, R | 1 |
| Verstappen, SM | 1 |
| van Roon, JA | 1 |
| Bijlsma, JW | 1 |
| Gross, WL | 1 |
| Tervaert, JW | 1 |
| Stegeman, CA | 1 |
| Kallenberg, CG | 1 |
7 reviews available for leflunomide and Vasculitis
| Article | Year |
|---|---|
Interventions for preventing and treating kidney disease in IgA vasculitis.
Topics: Adult; Child; Fosinopril; Humans; IgA Vasculitis; Kidney Diseases; Leflunomide; Proteinuria; Tacroli | 2023 |
Perforating disorder secondary to leflunomide and review of the literature of medications associated with perforating disorder.
Topics: Adult; Drug Eruptions; Elastin; Epidermis; Female; Humans; Immunosuppressive Agents; Leflunomide; Sk | 2018 |
Newer therapies for vasculitis.
Topics: Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Immunoglobulins, Intravenous; Immunosuppre | 2009 |
[Diagnosis and management of small vessel vasculitides].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal; Antibodies, Mono | 2010 |
What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides.
Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Et | 2005 |
New concepts in treatment protocols for severe systemic vasculitis.
Topics: Cyclophosphamide; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucoco | 1999 |
Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antilymphocyte Serum; Cyclophosphamide; Guanidines; Humans; | 2001 |
1 trial available for leflunomide and Vasculitis
| Article | Year |
|---|---|
Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.
Topics: Adult; Aniline Compounds; Crotonates; Diarrhea; Facial Dermatoses; Fatigue; Female; Humans; Hydroxyb | 2007 |
6 other studies available for leflunomide and Vasculitis
| Article | Year |
|---|---|
Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Immuno | 2002 |
Leflunomide induced vasculitis--a dose-response relationship.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Eruptions; Humans; Isoxazoles; Leflunomide; Male; Midd | 2003 |
Extraarticular rheumatoid arthritis and drug-induced syndromes: understanding the role of tumor necrosis factor inhibitors.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Infliximab; Isoxazoles; | 2004 |
Vasculitis associated with the use of leflunomide.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Le | 2004 |
Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy.
Topics: Aged; Arthritis, Rheumatoid; Cholestyramine Resin; Debridement; Female; Humans; Immunosuppressive Ag | 2005 |
Peripheral neuropathy associated with leflunomide: is there a risk patient profile?
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Complications; | 2007 |